Weak nausea drug data knocks back Tesaro shares

[riky]

Weak nausea drug data knocks back Tesaro shares

(Reuters) - Tesaro Inc's experimental drug for treating chemotherapy-induced nausea and vomiting (CINV) failed to show enough benefit in trials to give it an edge over competing drugs, sending its shares down as much as 24 percent. Merck & Co Inc's Emend, a drug similar to Tesaro's rolapitant, is approved to treat CINV and can help prevent it for up to 5 days from when chemotherapy is given. Two late-stage trials showed that while rolapitant was effective in treating CINV during the 24-120 hour period following chemotherapy, it failed to significantly improve patients' condition during the first 24 hours. Patients in the trials either received a combination of two drugs to reduce the side effects of chemotherapy or rolapitant plus the two-drug combo.

Source: You are not allowed to view links. Register or Login